Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Net Cash Flow (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Net Cash Flow for 4 consecutive years, with -$11.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 173.72% year-over-year to -$11.2 million, compared with a TTM value of -$40.9 million through Sep 2025, down 122.8%, and an annual FY2024 reading of -$811000.0, up 98.79% over the prior year.
  • Net Cash Flow was -$11.2 million for Q3 2025 at Atara Biotherapeutics, down from $2.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $26.6 million in Q4 2022 and bottomed at -$44.2 million in Q1 2023.
  • Average Net Cash Flow over 4 years is -$6.8 million, with a median of -$4.5 million recorded in 2022.
  • Peak annual rise in Net Cash Flow hit 438.95% in 2023, while the deepest fall reached 890.39% in 2023.
  • Year by year, Net Cash Flow stood at $26.6 million in 2022, then tumbled by 246.27% to -$38.9 million in 2023, then soared by 45.0% to -$21.4 million in 2024, then soared by 47.9% to -$11.2 million in 2025.
  • Business Quant data shows Net Cash Flow for ATRA at -$11.2 million in Q3 2025, $2.9 million in Q2 2025, and -$11.2 million in Q1 2025.